Prognostic significance of STAT3/phosphorylated-STAT3 in tumor: A meta-analysis of literatures

International Journal of Clinical and Experimental Medicine

Volumn 8, Issue 6, 2015, Pages 8525-8539

  Kong, Hongyu ^a   Zhang, Qiongwen ^a   Zeng, Yunhui ^a   Wang, Hong ^a   Wu, Mengqian ^a   Zheng, Tianying ^a   Zeng, Yanzhang ^a   Shi, Huashan ^a  

^a SICHUAN UNIVERSITY   (China)

Author keywords

Meta analysis; Prognosis; STAT3 phosphorylated STAT3; Tumor

Indexed keywords

STAT3 PROTEIN;

ARTICLE; CANCER PROGNOSIS; CANCER STAGING; CANCER SURVIVAL; CARCINOMA; DISEASE FREE SURVIVAL; HUMAN; IMMUNOHISTOCHEMISTRY; META ANALYSIS; NEOPLASM; NONHUMAN; OVERALL SURVIVAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; WESTERN BLOTTING;

EID: 84938399515     PISSN: None     EISSN: 19405901     Source Type: Journal    
DOI: None     Document Type: Article

References (49)

1. [1] Yu H and Jove R. The STATs of cancer--new molecular targets come of age. Nat Rev Cancer 2004; 4: 97-105.
2. [2] Bromberg JF, Wrzeszczynska MH, Devgan G, Zhao Y, Pestell RG, Albanese C and Darnell JE Jr. Stat3 as an Oncogene. Cell 1999; 98: 295-303.
3. [3] Frank DA. STAT signaling in the pathogenesis and treatment of cancer. Mol Med 1999; 5: 432-456.
4. [4] Choi JH, Ahn MJ, Park CK, Han HX, Kwon SJ, Lee YY and Kim IS. Phospho-Stat3 expression and correlation with VEGF, p53, and Bcl-2 in gastric carcinoma using tissue microarray. Apmis 2006; 114: 619-625.
5. [5] Hao M and Zhao WH. Constitutive activation of signal transducer and activator of transcription 3 in epithelial ovarian carcinoma. J Obstet Gynaecol Res 2009; 35: 918-925.
6. [6] Ying M, Li D, Yang L, Wang M, Wang N, Chen Y, He M and Wang Y. Loss of SOCS3 expression is associated with an increased risk of recurrent disease in breast carcinoma. J Cancer Res Clin Oncol 2010; 136: 1617-1626.
7. [7] Sonnenblick A, Uziely B, Nechushtan H, Kadouri L, Galun E, Axelrod JH, Katz D, Daum H, Hamburger T, Maly B, Allweis TM and Peretz T. Tumor STAT3 tyrosine phosphorylation status, as a predictor of benefit from adjuvant chemotherapy for breast cancer. Breast Cancer Res Treat 2013; 138: 407-413.
8. [8] Wang YC, Zheng LH, Ma BA, Zhou Y, Zhang MH, Zhang DZ and Fan QY. Clinical value of signal transducers and activators of transcription 3 (STAT3) gene expression in human osteosarcoma. Acta Histochem 2011; 113: 402-408.
9. [9] Gong W, Wang L, Yao JC, Ajani JA, Wei D, Aldape KD, Xie K, Sawaya R and Huang S. Expression of activated signal transducer and activator of transcription 3 predicts expression of vascular endothelial growth factor in and angiogenic phenotype of human gastric cancer. Clin Cancer Res 2005; 11: 1386-1393.
10. [10] Yakata Y, Nakayama T, Yoshizaki A, Kusaba T, Inoue K and Sekine I. Expression of p-STAT3 in human gastric carcinoma: significant correlation in tumour invasion and prognosis. Int J Oncol 2007; 30: 437-442.
11. [11] Woo S, Lee BL, Yoon J, Cho SJ, Baik TK, Chang MS, Lee HE, Park JW, Kim YH and Kim WH. Constitutive activation of signal transducers and activators of transcription 3 correlates with better prognosis, cell proliferation and hypoxia-inducible factor-1alpha in human gastric cancer. Pathobiology 2011; 78: 295-301.
12. [12] Chang KC, Wu MH, Jones D, Chen FF and Tseng YL. Activation of STAT3 in thymic epithelial tumours correlates with tumour type and clinical behaviour. J Pathol 2006; 210: 224-233.
13. [13] Parmar MK, Torri V and Stewart L. Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Stat Med 1998; 17: 2815-2834.
14. [14] Egger M, Davey Smith G, Schneider M and Minder C. Bias in meta-analysis detected by a simple, graphical test. Bmj 1997; 315: 629-634.
15. [15] Widschwendter A, Tonko-Geymayer S, Welte T, Daxenbichler G, Marth C and Doppler W. Prognostic significance of signal transducer and activator of transcription 1 activation in breast cancer. Clin Cancer Res 2002; 8: 3065-3074.
16. [16] Chen Y, Wang J, Wang X, Liu X, Li H, Lv Q, Zhu J, Wei B and Tang Y. STAT3, a Poor Survival Predicator, Is Associated with Lymph Node Metastasis from Breast Cancer. J Breast Cancer 2013; 16: 40-49.
17. [17] Do SI, Jung WW, Kim HS and Park YK. The expression of epidermal growth factor receptor and its downstream signaling molecules in osteosarcoma. Int J Oncol 2009; 34: 797-803.
18. [18] Jia Y, Liu D, Xiao D, Ma X, Han S, Zheng Y, Sun S, Zhang M, Gao H, Cui X and Wang Y. Expression of AFP and STAT3 is involved in arsenic trioxide-induced apoptosis and inhibition of proliferation in AFP-producing gastric cancer cells. PLoS One 2013; 8: e54774.
19. [19] Li C, Wang Z, Liu Y, Wang P and Zhang R. STAT3 expression correlates with prognosis of thymic epithelial tumors. J Cardiothorac Surg 2013; 8: 92.
20. [20] Benekli M, Xia Z, Donohue KA, Ford LA, Pixley LA, Baer MR, Baumann H and Wetzler M. Constitutive activity of signal transducer and activator of transcription 3 protein in acute myeloid leukemia blasts is associated with short disease-free survival. Blood 2002; 99: 252-257.
21. [21] Tu Y, Zhong Y, Fu J, Cao Y, Fu G, Tian X and Wang B. Activation of JAK/STAT signal pathway predicts poor prognosis of patients with gliomas. Med Oncol 2011; 28: 15-23.
22. [22] Zhang B, Zhong DW, Wang QW, Miao XY, Dai WD, Liu C and Pan KH. [Study on correlation of JAK/STAT signal pathway with progression and prognosis in hepatocellular carcinoma]. Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi 2010; 26: 368-370, 373.
23. [23] Zhao Y, Zhang J, Xia H, Zhang B, Jiang T, Wang J, Chen X and Wang Y. Stat3 is involved in the motility, metastasis and prognosis in lingual squamous cell carcinoma. Cell Biochem Funct 2012; 30: 340-346.
24. [24] Zhao M, Gao FH, Wang JY, Liu F, Yuan HH, Zhang WY and Jiang B. JAK2/STAT3 signaling pathway activation mediates tumor angiogenesis by upregulation of VEGF and bFGF in non-small-cell lung cancer. Lung Cancer 2011; 73: 366-374.
25. [25] Zhang LJ, Liu W, Gao YM, Qin YJ and Wu RD. The expression of IL-6 and STAT3 might predict progression and unfavorable prognosis in Wilms’ tumor. Biochem Biophys Res Commun 2013; 435: 408-413.
26. [26] Haura EB, Zheng Z, Song L, Cantor A and Bepler G. Activated epidermal growth factor receptor-Stat-3 signaling promotes tumor survival in vivo in non-small cell lung cancer. Clin Cancer Res 2005; 11: 8288-8294.
27. [27] Piperi C, Samaras V, Levidou G, Kavantzas N, Boviatsis E, Petraki K, Grivas A, Barbatis C, Varsos V, Patsouris E and Korkolopoulou P. Prognostic significance of IL-8-STAT-3 pathway in astrocytomas: correlation with IL-6, VEGF and microvessel morphometry. Cytokine 2011; 55: 387-395.
28. [28] Morikawa T, Baba Y, Yamauchi M, Kuchiba A, Nosho K, Shima K, Tanaka N, Huttenhower C, Frank DA, Fuchs CS and Ogino S. STAT3 expression, molecular features, inflammation patterns, and prognosis in a database of 724 colorectal cancers. Clin Cancer Res 2011; 17: 1452-1462.
29. [29] Schoppmann SF, Jesch B, Friedrich J, Jomrich G, Maroske F and Birner P. Phosphorylation of signal transducer and activator of transcription 3 (STAT3) correlates with Her-2 status, carbonic anhydrase 9 expression and prognosis in esophageal cancer. Clin Exp Metastasis 2012; 29: 615-624.
30. [30] Wu WY, Li J, Wu ZS, Zhang CL and Meng XL. STAT3 activation in monocytes accelerates liver cancer progression. BMC Cancer 2011; 11: 506.
31. [31] Ryu K, Choy E, Yang C, Susa M, Hornicek FJ, Mankin H and Duan Z. Activation of signal transducer and activator of transcription 3 (Stat3) pathway in osteosarcoma cells and overexpression of phosphorylated-Stat3 correlates with poor prognosis. J Orthop Res 2010; 28: 971-978.
32. [32] Chen CC, Chen WC, Lu CH, Wang WH, Lin PY, Lee KD and Chen MF. Significance of interleukin-6 signaling in the resistance of pharyngeal cancer to irradiation and the epidermal growth factor receptor inhibitor. Int J Radiat Oncol Biol Phys 2010; 76: 1214-1224.
33. [33] Xu YH and Lu S. A meta-analysis of STAT3 and phospho-STAT3 expression and survival of patients with non-small-cell lung cancer. Eur J Surg Oncol 2014; 40: 311-317.
34. [34] Jin L, Yuan RQ, Fuchs A, Yao Y, Joseph A, Schwall R, Schnitt SJ, Guida A, Hastings HM, Andres J, Turkel G, Polverini PJ, Goldberg ID and Rosen EM. Expression of interleukin-1beta in human breast carcinoma. Cancer 1997; 80: 421-434.
35. [35] Sieweke MH, Thompson NL, Sporn MB and Bissell MJ. Mediation of wound-related Rous sarcoma virus tumorigenesis by TGF-beta. Science 1990; 248: 1656-1660.
36. [36] Allavena P, Sica A, Solinas G, Porta C and Mantovani A. The inflammatory micro-environment in tumor progression: the role of tumor-associated macrophages. Crit Rev Oncol Hematol 2008; 66: 1-9.
37. [37] Luo Y, Zhou H, Krueger J, Kaplan C, Lee SH, Dolman C, Markowitz D, Wu W, Liu C, Reisfeld RA and Xiang R. Targeting tumor-associated macrophages as a novel strategy against breast cancer. J Clin Invest 2006; 116: 2132-2141.
38. [38] Boucher MJ, Morisset J, Vachon PH, Reed JC, Laine J and Rivard N. MEK/ERK signaling pathway regulates the expression of Bcl-2, Bcl-X(L), and Mcl-1 and promotes survival of human pancreatic cancer cells. J Cell Biochem 2000; 79: 355-369.
39. [39] Masuda M, Suzui M, Yasumatu R, Nakashima T, Kuratomi Y, Azuma K, Tomita K, Komiyama S and Weinstein IB. Constitutive activation of signal transducers and activators of transcription 3 correlates with cyclin D1 overexpression and may provide a novel prognostic marker in head and neck squamous cell carcinoma. Cancer Res 2002; 62: 3351-3355.
40. [40] Schmitz J, Weissenbach M, Haan S, Heinrich PC and Schaper F. SOCS3 exerts its inhibitory function on interleukin-6 signal transduction through the SHP2 recruitment site of gp130. J Biol Chem 2000; 275: 12848-12856.
41. [41] Kong F, Guo X, Noel JG, Wells DA, Lovell GJ and Ogle CK. Thermal injury-induced increases of hepatocyte SOCS3 lead to decreases in STAT3. Shock 2002; 18: 374-379.
42. [42] Begg CB and Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics 1994; 50: 1088-1101.
43. [43] Biljana M, Jelena M, Branislav J and Milorad R. Bias in meta-analysis and funnel plot asymmetry. Stud Health Technol Inform 1999; 68: 323-328.
44. [44] Xu TC, Li X, Wang WL, Hu P and Du FL. Detection of publication bias in meta-analysis of dichotomous variable-Egger test and Begg test. J Evidence-Based Med 2009; 19: 181-184.
45. [45] Zheng HL, Wang ZX and Wang ZZ. Applying the SAS Program to the Complete Begg’s Test, the Egger’s Test, and the Macaskill’s Test for Publication Bias of Meta-analysis. Chin J Evid-based Med 2009; 9: 910-916.
46. [46] Wang Z, Zhang YH and Xu QQ. Introduction of some methods for publication bias. Chinese Journal of Health Statistics 2009; 29: 539-541.
47. [47] Simon R and Altman DG. Statistical aspects of prognostic factor studies in oncology. Br J Cancer 1994; 69: 979-985.
48. [48] Ownby RL, Crocco E, Acevedo A, John V and Loewenstein D. Depression and risk for Alzheimer disease: systematic review, meta-analysis, and metaregression analysis. Arch Gen Psychiatry 2006; 63: 530-538.
49. [49] Higgins JP, Thompson SG, Deeks JJ and Altman DG. Measuring inconsistency in meta-analysis. BMJ 2003; 327: 557-560.